Integrating new approaches for clinical development: Translational research and relative effectiveness

Journal of Comparative Effectiveness Research

Volumn 1, Issue 1 SUPPL.1, 2012, Pages 15-21

  Lehner, Jean Pierre ^a   Epstein, Robert S ^b   Salimi, Tehseen ^a  

^a SANOFI   (France)

^b Medco Health Solutions   (United States)

Author keywords

drug development; observational studies; personalized medicine; randomized controlled trials; relative effectiveness; translational research

Indexed keywords

APPLIED RESEARCH; CLINICAL DECISION MAKING; CLINICAL DEVELOPMENT PLAN; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG DEVELOPMENT; HEALTH CARE NEED; HEALTH PROGRAM; HUMAN; NEEDS ASSESSMENT; OBSERVATIONAL STUDY; PATIENT CARE; PATIENT PREFERENCE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; REVIEW; TRANSLATIONAL RESEARCH;

EID: 84886945185     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.11.4     Document Type: Review

References (28)

1. Woolf SH. The meaning of translational research and why it matters. JAMA 299(2), 211-213 (2008).
2. Szilagyi PG. Translational research and pediatrics. Acad. Pediatr. 9(2), 71-80 (2009).
3. Khoury MJ, Gwinn M, Yoon PW, Dowling N, Moore CA, Bradley L. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet. Med. 9(10), 665-674 (2007).
4. Zerhouni EA. Translational research: moving discovery to practice. Clin. Pharmacol. Ther. 81(1), 126-128 (2007).
5. Sung NS, Crowley WF, Genel M et al. Central challenges facing the national clinical research enterprise. JAMA 289(10), 1278-1287 (2003).
6. Avorn J, Fischer M. 'Bench to behavior': translating comparative effectiveness research into improved clinical practice. Health Aff. (Millwood) 29(10), 1891-1900 (2010).
7. Lenfant C. Shattuck lecture - clinical research to clinical practice - lost in translation? N. Engl. J. Med. 349(9), 868-874 (2003).
8. Helfand M, Tunis S, Whitlock EP et al. A CTSA agenda to advance methods for comparative effectiveness research. Clin. Transl. Sci. 4(3), 188-198 (2011).
9. Eichler HG, Bloechl-Daum B, Abadie E, Barnett D, Konig F, Pearson S. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat. Rev. Drug Discov. 9(4), 277-291 (2010).
10. Hochman M, McCormick D. Characteristics of published comparative effectiveness studies of medications. JAMA 303(10), 951-958 (2010).
11. Stafford RS, Wagner TH, Lavori PW. New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N. Engl. J. Med. 361(13), 1230-1233 (2009).
12. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann. Intern. Med. 151(3), 203-205 (2009).
13. Chokshi DA, Avorn J, Kesselheim AS. Designing comparative effectiveness research on prescription drugs: lessons from the clinical trial literature. Health Aff. (Millwood) 29(10), 1842-1848 (2010).
14. Epstein RS, Teagarden JR. Comparative effectiveness research and personalized medicine: catalyzing or colliding? Pharmacoeconomics 28(10), 905-913 (2010).
15. Gartlehner G, Hansen RA, Nissman D, Lohr KN, Carey TS. A simple and valid tool distinguished efficacy from effectiveness studies. J. Clin. Epidemiol. 59(10), 1040- 1048 (2006).
16. Epstein R, Teagarden JR. Comparative effectiveness and personalized medicine: evolving together or apart? Health Aff. (Millwood) 29(10), 1783-1787 (2010).
17. Green LW, Glasgow RE. Evaluating the relevance, generalization, and applicability of research: issues in external validation and translation methodology. Eval. Health Prof. 29(1), 126-153 (2006).
18. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 302(13), 1437-1443 (2009).
19. Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco- Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55(25), 2804-2812 (2010).
20. Tinetti ME, Studenski SA. Comparative effectiveness research and patients with multiple chronic conditions. N. Engl. J. Med. 364(26), 2478-2481 (2011).
21. Conway PH, Clancy C. Charting a path from comparative effectiveness funding to improved patient-centered health care. JAMA 303(10), 985-986 (2010).
22. Dreyer NA, Tunis SR, Berger M, Ollendorf D, Mattox P, Gliklich R. Why observational studies should be among the tools used in comparative effectiveness research. Health Aff. (Millwood) 29(10), 1818-1825 (2010).
23. Fleurence RL, Naci H, Jansen JP. The critical role of observational evidence in comparative effectiveness research. Health Aff. (Millwood) 29, 1826-1833 (2010).
24. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6, 358-370 (2006).
25. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD. Chest 136, 734-743 (2009).
26. Alexeeff SE, Litonjua AA, Sparrow D, Vokonas PS, Schwartz J. Statin use reduces decline in lung function: VA normative aging study. Am. J. Respir. Crit. Care Med. 176, 742-747 (2007).
27. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58, 399-404 (2003).
28. Whitcomb DC. Going MAD: development of a "matrix academic division" to facilitate translating research to personalized medicine. Acad. Med. (2011) (Epub ahead of print).